For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

Neurons that secrete the neuropeptide orexin help mice decide between exercise and snacking. I n neurobiologist Daria ...

More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Problems with sleep likely develop before motor symptoms in people with amyotrophic lateral sclerosis, a new study shows.

However, Belsomra may be better for helping you maintain sleep throughout the night. Belsomra is an orexin receptor antagonist. Orexin is a neurotransmitter, a chemical in the brain that attaches ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.